AZD2461: Novel PARP Inhibitor for Overcoming Drug Resistance in Breast Cancer Research

Executive Summary: AZD2461 is a potent, selective poly (ADP-ribose) polymerase (PARP) inhibitor with an IC₅₀ of 5 nM, designed for research on DNA repair and cell death pathways (APExBIO). In vitro, AZD2461 induces concentration- and time-dependent cytotoxicity in human breast cancer cell lines MCF-7 and SKBR-3 (Schwartz 2022, DOI). The compound causes G2 phase cell cycle arrest and suppresses S-phase progression by inhibiting PARP-1 enzymatic activity. In vivo studies in mouse KB1P tumor models show complete PARP inhibition for hours post-treatment, with relapse-free survival doubled compared to controls. AZD2461, provided by APExBIO, exhibits low affinity for P-glycoprotein and bypasses Pgp-mediated resistance, making it a valuable resource for cancer and DNA damage response research.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes are critical mediators of DNA damage repair, particularly in the base excision repair (BER) pathway. Inhibiting PARP activity sensitizes cancer cells to DNA-damaging agents and exploits synthetic lethality, especially in BRCA1-mutated tumors with homologous recombination (HR) defects (Schwartz 2022). PARP inhibitors, such as AZD2461, serve as research tools to dissect DNA repair mechanisms, programmed cell death, and resistance pathways. AZD2461's design addresses limitations of earlier inhibitors, enabling studies of Pgp-mediated drug resistance and relapse prevention in advanced breast cancer models. The compound's robust solubility in DMSO and ethanol and its stability at -20°C make it suitable for both in vitro and in vivo workflows (APExBIO).

Mechanism of Action of AZD2461

AZD2461 functions as a selective inhibitor of PARP-1, binding with nanomolar affinity (IC₅₀ = 5 nM). Upon binding, it blocks PARP-1 catalytic activity, preventing poly (ADP-ribosyl)ation of target proteins and thus inhibiting single-strand DNA break repair. This blockade leads to accumulation of DNA damage, G2 phase cell cycle arrest, and ultimately, cell death in susceptible cancer cells. In breast cancer cell lines (MCF-7, SKBR-3), AZD2461 treatment (5–50 μM, 48–72 h) results in reduced viable cell numbers and an altered cell cycle profile, with a marked increase in G2 phase and decrease in S phase populations (Schwartz 2022). In vivo, AZD2461 administration in KB1P tumor-bearing mice leads to near-complete and sustained PARP inhibition for several hours, with recovery of PAR levels to baseline by 24 h post-dose (APExBIO).

Evidence & Benchmarks

• AZD2461 exhibits an IC₅₀ of 5 nM against PARP-1, demonstrating high potency (APExBIO).
• In MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces viability in a concentration- and time-dependent manner, with significant cytotoxic effects observed at 5–50 μM over 48–72 hours (Schwartz 2022, Fig. 3.11).
• AZD2461 induces G2 phase cell cycle arrest, increasing G2/M population and reducing S-phase cells, as quantified by flow cytometry (Schwartz 2022, Table 3.2).
• In vivo, AZD2461 completely inhibits PARP activity in mouse KB1P tumor models for several hours post-administration, with PAR levels returning to baseline after 24 hours (APExBIO).
• Long-term AZD2461 administration in mice is well tolerated and extends median relapse-free survival from 64 to 132 days in BRCA1-mutated tumor models (APExBIO).
• AZD2461's lower affinity for P-glycoprotein enables bypass of Pgp-mediated drug resistance, a principal limitation of other PARP inhibitors (Schwartz 2022, Discussion).

For additional mechanistic and translational context, see the internal review "AZD2461 and the Future of PARP-1 Inhibition", which provides a molecular perspective but does not cover the latest in vivo benchmarks or storage stability addressed here.

Applications, Limits & Misconceptions

AZD2461 is optimized for research in cell-based and animal cancer models, particularly those involving DNA repair pathway modulation, PARP-1 inhibition, and studies of Pgp-mediated resistance. Its solubility in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL) supports diverse laboratory workflows. The compound is a research-use-only reagent and is not intended for clinical or diagnostic applications.

Common Pitfalls or Misconceptions

• AZD2461 is not a broad-spectrum cytotoxin: Its cytotoxicity is context-dependent, with greatest efficacy in cell lines or models harboring DNA repair deficiencies (e.g., BRCA1 mutations).
• Not water-soluble: AZD2461 is insoluble in aqueous buffers; improper dissolution may yield inconsistent results.
• Pgp-resistance bypass is not universal: While AZD2461 shows reduced Pgp affinity, resistance mechanisms unrelated to Pgp can still limit efficacy.
• Not a clinical therapeutic: AZD2461 is for laboratory research use only and is not approved for human therapy.
• Short-term solution stability: Stock solutions are recommended for short-term use only, as long-term storage in solution may reduce potency (APExBIO).

For a comparative view of resistance mechanisms, see "AZD2461: Advanced PARP-1 Inhibition for Next-Generation Cancer Research". This article supplements those findings with explicit storage and workflow guidance.

Workflow Integration & Parameters

AZD2461 (A4164) is supplied as a solid (MW: 395.43, C₂₂H₂₂FN₃O₃) and should be stored at -20°C. For in vitro assays, dissolve in DMSO or ethanol with ultrasonic assistance. Experimental conditions typically use 5–50 μM for 48–72 hours in breast cancer cell cultures. For in vivo studies, dosing regimens should follow published benchmarks for mouse tumor models (see above). Always use fresh solutions and avoid repeated freeze-thaw cycles. For detailed in vitro protocols and advanced in vivo applications, see "AZD2461: Redefining PARP Inhibition Through Systems Biology"; the present article provides updated parameters and highlights recent advances in relapse prevention and resistance bypass.

Conclusion & Outlook

AZD2461 is a state-of-the-art PARP-1 inhibitor with validated efficacy in DNA repair pathway research, particularly for breast cancer and BRCA1-mutated tumor models. Its ability to bypass Pgp-mediated resistance, induce G2 phase arrest, and extend relapse-free survival in vivo makes it a preferred tool for mechanistic and translational cancer biology studies. As shown by APExBIO and recent peer-reviewed research (Schwartz 2022), AZD2461 advances both in vitro and in vivo exploration of PARP inhibitor resistance and DNA damage response modulation. Future studies will further elucidate its role in overcoming multidrug resistance and optimizing combination therapies for advanced cancers.